Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19

Simple item page
dc.contributor.authorÖzdemir İ.H.
dc.contributor.authorÖzlek B.
dc.contributor.authorÖzen M.B.
dc.contributor.authorGündüz R.
dc.contributor.authorÇetin N.
dc.contributor.authorBilge A.R.
dc.date.accessioned2024-07-22T08:06:09Z
dc.date.available2024-07-22T08:06:09Z
dc.date.issued2021
dc.description.abstractBackground: Hydroxychloroquine (HCQ) and azithromycin (AZM) are widely used in off-label treatment of novel coronavirus disease (COVID-19). However, cardiac safety of these drugs is still controversial in COVID-19. Therefore, we aimed to evaluate association of HCQ or HCQ + AZM treatment regimens, corrected QT (QTc) interval and malignant ventricular arrhythmias in hospitalized patients. Methods: This is a single-center, retrospective and observational study. All data were extracted from the electronic medical records. The initial and post-treatment mean QTc intervals were calculated and compared in patients with HCQ alone or HCQ + AZM therapy. Associated factors with QTc prolongation, the incidence of ventricular arrhythmia during treatment and in-hospital mortality because of ventricular arrhythmias were evaluated. Results: Our cohort comprised 101 hospitalized COVID-19 patients (mean age of 49.60 ± 18 years, 54.4% men). HCQ + AZM combination therapy group (n = 56) was more likely to have comorbidities. After 5-days treatment, 19 (18.8%) patients had QTc prolongation, and significant increase in the QTc interval was observed in both two groups (P <.001). However, HCQ + AZM combination group had significantly higher ΔQTc compared to HCQ group (22.5 ± 18.4 vs 7.5 ± 15.3 ms, P <.001). All of 101 patients completed the 5-days treatment without interruption. Also, no malignant ventricular arrhythmia or death secondary to ventricular arrhythmia occurred during the treatment in both groups. Conclusions: The present study revealed that although HCQ + AZM treatment was independently associated with QTc prolongation, none of patients experienced malignant ventricular arrhythmia or death during treatment. Further prospective studies are needed to determine the exact implications of these drugs on arrhythmias in patients with COVID-19. © 2020 John Wiley & Sons Ltd
dc.identifier.DOI-ID10.1111/ijcp.13896
dc.identifier.issn13685031
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13378
dc.language.isoEnglish
dc.publisherBlackwell Publishing Ltd
dc.rightsAll Open Access; Gold Open Access
dc.subjectAdult
dc.subjectAged
dc.subjectAnti-Bacterial Agents
dc.subjectArrhythmias, Cardiac
dc.subjectAzithromycin
dc.subjectComorbidity
dc.subjectCOVID-19
dc.subjectDrug Therapy, Combination
dc.subjectElectrocardiography
dc.subjectFemale
dc.subjectHumans
dc.subjectHydroxychloroquine
dc.subjectLong QT Syndrome
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectRetrospective Studies
dc.subjectSARS-CoV-2
dc.subjectazithromycin
dc.subjecthydroxychloroquine
dc.subjectantiinfective agent
dc.subjectazithromycin
dc.subjecthydroxychloroquine
dc.subjectadult
dc.subjectaging
dc.subjectArticle
dc.subjectcohort analysis
dc.subjectcomorbidity
dc.subjectcomparative study
dc.subjectcoronavirus disease 2019
dc.subjectdisease association
dc.subjectdrug safety
dc.subjectelectronic medical record
dc.subjectfemale
dc.subjectheart ventricle arrhythmia
dc.subjecthospital mortality
dc.subjecthospitalization
dc.subjecthuman
dc.subjectincidence
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmiddle aged
dc.subjectmonotherapy
dc.subjectobservational study
dc.subjectpriority journal
dc.subjectQT interval
dc.subjectQT prolongation
dc.subjectQTc interval
dc.subjectretrospective study
dc.subjectaged
dc.subjectcombination drug therapy
dc.subjectelectrocardiography
dc.subjectheart arrhythmia
dc.subjectlong QT syndrome
dc.titleHydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19
dc.typeArticle

Files

Collections

Scopus Koleksiyonu